Medivir gets 2,6 MUSD following regulatory approval to start clinical trials with the HIV antiviral MIV-150

Medivir gets 2,6 MUSD following regulatory approval to start clinical trials with the HIV antiviral MIV-150 Medivir receives a 2,6 MUSD milestone payment following Chiron's receipt of clearance from the relevant authority to start clinical trials in the UK. Earlier this year Medivir outlicenced the HIV antiviral substance MIV-150 to Chiron Corporation. The agreement gave Chiron the exclusive rights to the global marketing and sales of the HIV drug MIV-150. Medivir received 5 MUSD on signing. If MIV-150 is successful, Medivir would receive up to a total of 35 MUSD upon reaching specified milestones, as well as royalties up to the year 2017, under the Chiron contract. Medivir recently received 3 MUSD as a milestone payment following a decision by Chiron to begin the regulatory process for initiating phase I clinical trials. In total Medivir has now received 10,6 MUSD this year for this project. Huddinge 16 August 1999 Medivir AB (publ) For more information please contact: Jonas Frick, Anna Bernsten, Vice President Business Development and Investor Relations, Medivir AB, phone no +46-8-608 31 05, +46-709-369 069 or e-mail: anna.bernsten@medivir.se. For more information about Medivir: www.medivir.se Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/08/16/19990816BIT00300/bit0001.doc http://www.bit.se/bitonline/1999/08/16/19990816BIT00300/bit0002.pdf

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe